Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Core Insights - Ultragenyx Pharmaceutical Inc. reported total revenue of $673 million for the year ended December 31, 2025, representing a 20% increase compared to the previous year [5][4] - The company has initiated a strategic restructuring plan aimed at reducing operating expenses and headcount, with a goal of achieving profitability by 2027 [9][10] - Key catalysts for 2026 include two potential product approvals and pivotal Phase 3 data from the GTX-102 study for Angelman syndrome [1][11] Financial Performance - In Q4 2025, total revenue was $207 million, a 25% increase from Q4 2024 [4][6] - Crysvita revenue for 2025 was $481 million, up 17% year-over-year, with significant growth in Latin America and Türkiye [5][6] - Dojolvi revenue for 2025 reached $96 million, reflecting a 9% increase compared to the prior year [5][6] Operating Expenses - Total operating expenses for Q4 2025 were $321 million, and for the full year, they amounted to $1.2 billion [7][6] - The company incurred a net loss of $129 million in Q4 2025, slightly improved from a net loss of $133 million in Q4 2024 [8][6] - For the year, the net loss was $575 million, compared to a net loss of $569 million in 2024 [8][6] Strategic Restructuring - The strategic restructuring plan includes a 10% workforce reduction, impacting approximately 130 employees [10] - Revenue guidance for 2026 is projected to be between $730 million and $760 million, indicating an 8% to 13% increase compared to 2025 [10] - The plan aims to align resources with high-impact opportunities and reduce costs to support future growth [9][10] Clinical and Regulatory Developments - The company expects pivotal data from the GTX-102 Phase 3 Aspire study in the second half of 2026 [11] - Anticipated regulatory actions include a PDUFA date for DTX401 in Q3 2026 and ongoing developments for UX111 and UX701 [15][11]